Success Stories

Event Videos

Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation J Gastroenterol Hepatol. 2013 Jul;28(7):1217-22. Matsuzaki T, Tatsuki I, Otani M, Akiyama M, Ozawa E, Miuma S, Miyaaki H, Taura N, Hayashi T, Okudaira S, Takatsuki M, Isomoto H, Takeshima F, Eguchi S, Nakao K. http://www.ncbi.nlm.nih.gov/pubmed/23432697 Abstract Published on: Jul-2013 Read more	Sustained Hepatitis C Virus Clearance and Increased Hepatitis B Surface Antigen Seroclearance in Patients With Dual Chronic Hepatitis C and B During Posttreatment Follow-Up Hepatology. 2013 Jun;57(6):2135-42 Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ; Taiwan Liver-Net Consortium. http://www.ncbi.nlm.nih.gov/pubmed/23322699 Published on: Jun-2013 Read more
Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis. J Gastroenterol Hepatol. 2013 Jul;28(7):1202-8. Salomone F, Li Volti G, Rosso C, Grosso G, Bugianesi E. http://www.ncbi.nlm.nih.gov/pubmed/23425054 Abstract Background and Aim: Oxidative stress is considered a key element in the progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis (NASH). Unconjugated bilirubin is the main endogenous lipid antioxidant and is cytoprotective in different tissues and organs. In this study, it was evaluated if unconjugated bilirubin levels are associated with the degree of liver injury in patients with non-alcoholic fatty liver disease. Methods: Two hundred and eighty-five patients were retrospectively evaluated with Published on: Jul-2013 Read more	Plasma Interferon-gamma-Inducible Protein-10 (IP-10) Levels During Acute Hepatitis C Virus Infection Hepatology. 2013 Jun;57(6):2124-34 Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, Petoumenos K, Zang G, Shaw I, Yeung B, George J, Teutsch S, Kaldor JM, Cherepanov V, Bruneau J, Shoukry NH, Lloyd AR, Dore GJ. http://www.ncbi.nlm.nih.gov/pubmed/23325615 Systemic levels of interferon-gamma-inducible protein-10 (IP-10) are predictive of treatment- induced clearance in chronic hepatitis C virus (HCV). In the present study, factors associated with plasma IP-10 levels at the time of acute HCV detection and the association between IP-10 levels and spontaneous clearance were assessed in three cohorts of acute HCV Published on: Jun-2013 Read more
Drug-induced Liver Injury Caused by Intravenously Administered Medications: The Drug-induced Liver Injury Network Experience J Clin Gastroenterol. 2013 Jul;47(6):553-8. Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N. http://www.ncbi.nlm.nih.gov/pubmed/23388845 Background and Aims: Idiosyncratic drug-induced liver injury (DILI) can be caused by intravenous (IV) medications, but the characteristics of DILI caused by these agents are not known. The aim of this study is to characterize the clinical features of subjects with suspected DILI associated with IV agents enrolled into the Drug Induced Liver Injury Network Prospective Study. Methods: Subjects with suspected DILI due to IV medications with probable, highly likely, or definite casuality scores were eligible. Published on: Jul-2013 Read more	Association of Tattooing and Hepatitis C Virus Infection: A Multicenter Case-Control Study Hepatology. 2013 Jun;57(6):2117-23 Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. http://www.ncbi.nlm.nih.gov/pubmed/23315899 Although injection drug use (IDU) and blood transfusions prior to 1992 are well-accepted risk factors for hepatitis C virus (HCV) infection, many studies that evaluated tattooing as a risk factor for HCV infection did not control for a history of IDU or transfusion prior to 1992. In this large, multicenter, case-control study, we analyzed demographic and HCV Published on: Jun-2013 Read more
Dietary Fructose Intake and Severity of Liver Disease in Hepatitis C Virus-infected Patients J Clin Gastroenterol 2013 Jul ;47:545–552 Tyson GL, Richardson PA, White DL, Kuzniarek J, Ramsey DJ, Tavakoli-Tabasi S, El-Serag HB. http://www.ncbi.nlm.nih.gov/pubmed/23426443 Background and Goals: Dietary fructose intake in the United States has been increasing, and fructose intake has been associated with the metabolic syndrome and hepatic steatosis. This study aimed to determine whether dietary fructose intake is associated with advanced hepatic fibrosis and inflammation in an hepatitis C virus (HCV)-infected male population. Published on: Jul-2013 Read more	Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era? Am J Gastroenterol. 2013 Jun;108(6):949-51. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era? Terrault N. http://www.ncbi.nlm.nih.gov/pubmed/23735916 Abstract Published on: Jun-2013 Read more
Cholestasis in a Patient With Gallstones and a Normal Gamma-Glutamyl Transferase Hepatology. 2013 Jun;57(6):2539-41. Moghadamrad S, Montani M, Weimann R, De Gottardi A. http://www.ncbi.nlm.nih.gov/pubmed/23446990 Cholestasis with normal gamma glutamyl transferase characterizes functional deficiencies in the gene ABCB11, which encodes the bile salt export pump (BSEP), a liver-specific adenosine triphosphate (ATP)-binding cassette transporter. Here we report the case of a patient presenting with features of benign recurrent intrahepatic cholestasis associated with a heterozygous mutation in the ABCB11 gene. Immunohistochemistry showed a gradual decrease of BSEP from zone 1 to zone 3 of the liver lobule, suggesting that the Published on: Jun-2013 Read more	Oral Nucleoside / Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B Am J Gastroenterol. 2013 Jun;108(6):942-8. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. http://www.ncbi.nlm.nih.gov/pubmed/23629601 OBJECTIVES: The long-term outcomes of oral antiviral therapy without hepatitis B immune globulin (HBIG) in prevention of reinfection with hepatitis B after liver transplantation are not known. We aimed to determine the long-term outcomes from a large population of chronic hepatitis B (CHB) liver transplant recipients using oral antiviral therapy alone. Published on: Jun-2013 Read more

CLF Intro movie

SMS requests to

9224791366

Ask The Expert

Pediatric Liver Specialists in India

Centres offering Genetic Testing for Pediatric Liver Diseases

Financial Aid Offered by Trusts

Follow us on:

Facebook Twitter YouTube